C3 GLOMERULONEPHRITIS
Clinical trials for C3 GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for C3 GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney diseases: early access drug available
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and kidney damage. Participants must have active disease and limited response to other treatments. The …
Matched conditions: C3 GLOMERULONEPHRITIS
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:14 UTC
-
New hope for rare kidney patients: Long-Term drug trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…
Matched conditions: C3 GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC